DENVER--(BUSINESS WIRE)--Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with injectable disease modifying therapies (DMTs) were presented and announced by Biogen Idec as poster presentations at the Consortium of Multiple Sclerosis Center (CMSC) annual meeting in Denver, Colorado, May 28-May 31, 2008. The results revealed that patients treated with AVONEX® (interferon beta-1a IM) reported significantly less sick leave, sick leave costs and short-term disability costs than patients treated with Copaxone® (glatiramer acetate).
